Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The spleen has been reported to inhibit liver regeneration following hepatectomy; however, the underlying mechanisms remain poorly understood. In particular, its role in future liver remnant (FLR) regeneration after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) warrants investigation.
Aim: To evaluate the relationship between splenic volume changes and FLR regeneration following ALPPS-stage I in patients with massive hepatocellular carcinoma (HCC).
Methods: Clinical data from 65 HCC patients who underwent ALPPS between 2018 and 2021 were retrospectively analyzed. Liver and spleen volumes were measured pre- and post-ALPPS-stage I use the IQQA-Liver system. The kinetic growth rate (KGR) of the FLR was calculated. Pearson correlation and logistic regression were used to identify predictors of FLR hypertrophy. Receiver operating characteristic (ROC) curves were constructed to determine cutoff values for splenic predictors.
Results: Following ALPPS-stage I, FLR volume significantly increased from 35.57%±8.51-54.31%±11.19% of standard liver volume (SLV) (P < 0.001), with a median KGR of 4.65%/day. Splenic volume also increased (218.65 ± 84.77 cm³ vs. 252.69 cm³, P < 0.001). Preoperative splenic volume and spleen volume/SLV ratio negatively correlated with KGR (r = -0.240, P = 0.027; r = -0.218, P = 0.041). Multivariate analysis identified splenic volume (OR = 0.991, P = 0.043), platelet count (OR = 1.014, P = 0.013), Indocyanine Green Retention Rate at 15 min (ICG-R15) (OR = 0.670, P = 0.010), and CNLC stage (P = 0.001) as independent predictors of FLR regeneration. ROC analysis showed that splenic volume > 265.29 cm³ (AUC = 0.645) and spleen volume/SLV ratio > 0.1997 (AUC = 0.646) predicted poor FLR hypertrophy. One- and two-year survival rates were 80.77% and 68.18%, respectively.
Conclusion: Preoperative splenic volume is an independent predictor of FLR regeneration after ALPPS. Combined evaluation of splenic volume, platelet count, and liver function may improve patient selection, reduce the risk of postoperative liver failure, and optimize surgical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000165 | PMC |
| http://dx.doi.org/10.1007/s00423-025-03698-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simultaneous Portal and Hepatic Vein Embolization versus Portal Vein Embolization Only in Patients with Hepatocellular Carcinoma: A Retrospective Review of Safety and Effectiveness.
J Vasc Interv Radiol
September 2025
Department of Radiology, Hanoi Medical University, Hanoi, Vietnam.
Purpose: To compare the safety and efficacy of simultaneous portal and hepatic vein embolization (PHVE) versus portal vein embolization (PVE) in enhancing future liver remnant (FLR) hypertrophy in patients with hepatocellular carcinoma (HCC).
Materials And Methods: This retrospective study included 97 patients with HCC who underwent transarterial chemoembolization (TACE) followed by PVE (n = 34) or PHVE (n = 63) for preoperative liver augmentation. Volumetric analysis using contrast-enhanced CT was performed at a median of 25 days (PHVE) and 31 days (PVE) post-embolization (P = .
Impact of CT-Assessed Liver Steatosis in Hepatic Regeneration and Surgical Outcome After Liver Venous Deprivation.
Cardiovasc Intervent Radiol
July 2025
Department of Radiology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.
Purpose: To evaluate the impact of CT-assessed liver steatosis (LS) on functional and volumetric hypertrophy in patients undergoing liver venous deprivation (LVD) prior major hepatectomy and surgical outcome.
Materials And Methods: A single-center retrospective analysis was conducted on patients undergoing LVD between June 2019 and September 2024. LS was defined as mean liver density < 45HU on pre-LVD unenhanced CT-scan.
First results from the international registry on liver venous deprivation (EuroLVD).
HPB (Oxford)
August 2025
Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland. Electronic address:
Background: An international registry on liver venous deprivation (LVD, simultaneous portal and hepatic vein embolization) was created in 2020. This study assessed the outcomes after LVD in patients included in the registry.
Methods: Eight international centers participated.
Mesenchymal Stem Cells Loaded in Injectable Alginate Hydrogels Promote Liver Growth and Attenuate Liver Fibrosis in Cirrhotic Rats.
Gels
March 2025
Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cirrhosis, a marker of severe liver diseases, limits future liver remnant (FLR) growth, preventing many cancer patients from undergoing surgery. While portal vein blockade (PVB) techniques are used to stimulate liver regeneration, 20-30% of patients still fail to achieve the required growth. Although mesenchymal stem cell (MSC) therapy improves PVB, its efficacy is limited by poor cell retention.
View Article and Find Full Text PDFSafety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial.
Lancet Reg Health Eur
June 2025
Department of Surgery, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
Background: Major liver resection is often required for complete clearance of colorectal liver metastases (CRLM). Patients with insufficient future liver remnant (FLR) volume/function are at high risk of post-hepatectomy liver failure (PHLF) and require FLR hypertrophy-inducing procedures to enable safe resection. The most recent variant of these procedures is combined portal and hepatic vein embolization (PVE/HVE).
View Article and Find Full Text PDF